Metatasis In Situ, Red is the fluorescence. Photo Dr. Franz Marhold
Physicians from Karl Landsteiner University of Health Sciences in Krems (KL Krems, Austria) present results of the world's most extensive study headed by the MedUni Vienna investigating the value of 5-aminolevulinic acid in surgery of brain metastases
Krems (Austria), May 19th – Two-thirds of brain metastases give off fluorescence following administration of 5-aminolevulinic acid, which could potentially assist surgeons in identifying such tumors. However, fluorescence patterns are often heterogeneous or vague, which limits their practical benefits. These were the key findings of a major study performed by Karl Landsteiner University of Health Sciences in Krems (KL Krems) and headed by the Medical University of Vienna, published in the Journal of Neurosurgery. The study looked at 150 patients, making this the world’s most comprehensive research project of its kind to date. It has also delivered significant results, which will form a valuable basis for developing this potentially useful technique.
Brain metastases are the most common type of tumor that affects the brain, occurring in 20-40 percent of all systemic cancers. They are often removed surgically, which is an important treatment option aside from radiotherapy, gamma knife radiosurgery or chemotherapy. In most cases, they can be effectively removed, as metastases can often be clearly distinguished from the surrounding tissue. However, recent research found that residual tumors remain after around 20 percent of surgical resections. Performing an operation after administering 5-aminolevulinic acid (5-ALA) could enable surgeons to pinpoint these hard-to-visualize parts of tumors during surgery. Particularly in tumor cells, 5-ALA creates easily recognizable fluorescence, which in turn simplifies identification of residual tumors. This already is an established method of treating primary brain tumors, but so far there has been no systematic investigation of its use in connection with brain metastases. This was what the team from KL Krems and MedUni Vienna set out to achieve in the largest study of its kind to be performed anywhere in the world – and their findings were sobering.
“We demonstrated visible fluorescence in two-thirds of all metastases following preoperative administration of 5-ALA,” explained Dr. Franz Marhold (Department of Neurosurgery, University Hospital St. Pölten, KL Krems ), lead author of the study, which was published in the Journal of Neurosurgery. “But this fluorescence was often vague and heterogeneously distributed, which unfortunately means its practical applicability is limited.” The researchers examined a total of 157 brain metastases in 154 patients. 5-ALA fluorescence was identified in 104 metastases, and 53 demonstrated no fluorescence. However, in over 80 percent of cases, fluorescence was so heterogeneous that it provided little support to the surgeons performing the resection.
A key feature of this wide-ranging study was the correlation between the fluorescence characteristics – status (i.e. visible or not), quality (i.e. intensity) and homogeneity – and the primary tumor type. According to Prof. Georg Widhalm of the Department of Neurosurgery at MedUni Vienna, who was the head of the study: “We mainly examined brain metastases in patients with lung, breast, colorectal and renal cell cancer, and melanoma. Our evaluation showed that visible fluorescence was observed most frequently in certain kinds of breast tumors, and least often in melanoma cases. The heterogeneous distribution and low intensity of fluorescence in the tumor was a feature shared by all forms of cancer.”
The researchers were unable to find the causes of the often vague fluorescence in brain metastases, but the data and tumor samples collected will pave the way for future research into the possible reasons. The same goes for the heterogeneous fluorescence within individual metastases. ““We suspect there are differences in the distribution of certain metabolites within a tumor. They react with 5-ALA, leading to heterogeneous levels of fluorescence,” Dr. Marhold commented. This is one of the questions that researchers will aim to address in future projects.
The work performed by the team headed by Dr. Marhold and Prof. Widhalm demonstrates the strong practical relevance of the neuro-oncological research carried out at KL Krems and MedUni Vienna. The research addresses the needs of day-to-day clinical practice, and makes a significant contribution to discovering, developing, improving and evaluating treatment options.
Karl Landsteiner University of Health Sciences (KL) is a pioneer for innovation in medical and health sciences education and research, and a catalyst for groundbreaking work which will benefit society at large. Research at KL focuses on niche fields in bridge disciplines such as molecular oncology and hematology, biomedical engineering, psychology and psychodynamics, as well as topics including water quality and related health issues. Study programmes include health sciences, human medicine, psychology, psychotherapy and counselling and have full European recognition. A network of university hospitals in St PoeltenPölten, Krems, and Tulln provides students with quality-assured, research-led education; it. It enables them to do internationally- recognized top-class clinical and translational research that is recognised worldwide. Karl Landsteiner University received accreditation by the Agency for Quality Assurance and Accreditation Austria (AQ Austria) in 2013.
Dr. Franz Marhold
Department of Neurosurgery
University Hospital St. Pölten
Karl Landsteiner University of Health Sciences 3100 St. Pölten
T +43 2742 9004-12961
W http://www.stpoelten.lknoe.atOriginal Publication: Detailed analysis of 5-aminolevulinic acid induced fluorescence in different brain metastases at two specialized neurosurgical centers: experience in 157 cases. F. Marhold, P.A. Mercea, F. Scheichel, A.S. Berghoff, P. Heicappell, B. Kiesel, M. Mischkulnig, M. Borkovec, S. Wolfsberger, A. Woehrer, M. Preusser, E. Knosp, K. Ungersboeck, G. Widhalm. J Neurosurg. doi: 10.3171/2019.6.JNS1997.